We are evaluating the safety and effectiveness of Furmonertinib for patients with non-small cell lung cancer who have specific EGFR or HER2 mutations. This study aims to see how well the drug works in treating this type of cancer.
Health conditions and diseases that the clinical trial is designed to study and treat.
Non-Small Cell Lung Cancer (NSCLC) is a type of lung cancer that includes several subtypes and is characterized by mutations in genes like EGFR and HER2. It is the most common form of lung cancer and can be aggressive, often requiring targeted therapies.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
